NRG Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nrgoncology.org
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Conditions
- Hard Palate Squamous Cell CarcinomaLip Squamous Cell CarcinomaStage I Lip and Oral Cavity Cancer AJCC v8Tongue Squamous Cell CarcinomaLower Alveolar Ridge Squamous Cell CarcinomaRetromolar Trigone Squamous Cell CarcinomaStage II Lip and Oral Cavity Cancer AJCC v8Buccal Mucosa Squamous Cell CarcinomaFloor of Mouth Squamous Cell CarcinomaGingival Squamous Cell Carcinoma
- Interventions
- Procedure: Chest RadiographyProcedure: Computed TomographyOther: Fludeoxyglucose F-18Procedure: Neck DissectionDrug: Imaging AgentProcedure: Planar ImagingProcedure: Positron Emission TomographyOther: Questionnaire AdministrationProcedure: Sentinel Lymph Node BiopsyProcedure: Single Photon Emission Computed Tomography
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 686
- Registration Number
- NCT04333537
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Conditions
- Ovarian Carcinoma
- Interventions
- Procedure: Bilateral SalpingectomyProcedure: Bilateral Salpingectomy with OophorectomyProcedure: Biospecimen CollectionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: Transvaginal UltrasoundProcedure: Ultrasound Imaging
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2262
- Registration Number
- NCT04251052
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
- Conditions
- Pleural Biphasic MesotheliomaPleural Epithelioid MesotheliomaStage I Pleural Malignant Mesothelioma AJCC v8Stage IA Pleural Malignant Mesothelioma AJCC v8Stage IB Pleural Malignant Mesothelioma AJCC v8Stage II Pleural Malignant Mesothelioma AJCC v8Stage IIIA Pleural Malignant Mesothelioma AJCC v8
- Interventions
- Procedure: DecorticationRadiation: Intensity-Modulated Radiation TherapyRadiation: Pencil beam scanning proton therapyProcedure: Pleurectomy
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 16
- Registration Number
- NCT04158141
- Locations
- 🇨🇦
The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇺🇸Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- Conditions
- Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Bone ScanProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 586
- Registration Number
- NCT04134260
- Locations
- 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Kaiser Permanente-Anaheim, Anaheim, California, United States
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
- Conditions
- Anaplastic AstrocytomaGlioblastomaOligodendrogliomaSupratentorial Glioblastoma
- Interventions
- Device: NovoTTF-100A DeviceOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Therapeutic Conventional SurgeryBiological: Vocimagene Amiretrorepvec
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- NRG Oncology
- Registration Number
- NCT04105374
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous AdenocarcinomaStage IV Primary Peritoneal Cancer AJCC v8Low Grade Fallopian Tube Serous AdenocarcinomaStage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Imaging Procedure
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 450
- Registration Number
- NCT04095364
- Locations
- 🇺🇸
Unity Hospital, Fridley, Minnesota, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- Conditions
- Colon AdenocarcinomaStage IIA Colon Cancer AJCC v8
- Interventions
- Other: Patient Observation
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 635
- Registration Number
- NCT04068103
- Locations
- 🇺🇸
Kaiser Permanente-Franklin, Denver, Colorado, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
- Conditions
- Prostate AdenocarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Biological: Gonadotrophin Releasing HormoneRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT04037254
- Locations
- 🇺🇸
Benefis Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
- Conditions
- Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 350
- Registration Number
- NCT03997370
- Locations
- 🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Other: Questionnaire AdministrationOther: Survivorship Care Plan (SCP)Other: Treatment Plan
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 546
- Registration Number
- NCT03860961
- Locations
- 🇺🇸
SSM Health Good Samaritan, Mount Vernon, Illinois, United States
🇺🇸Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸Kaiser Permanente Dublin, Dublin, California, United States